Citadel Advisors’s Tandem Diabetes Care TNDM Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $723K | Buy |
37,700
+2,700
| +8% | +$58.7K | ﹤0.01% | 8429 |
|
|
2025
Q4 | $769K | Sell |
35,000
-18,900
| -35% | -$341K | ﹤0.01% | 8005 |
|
|
2025
Q3 | $654K | Buy |
53,900
+15,900
| +42% | +$215K | ﹤0.01% | 8494 |
|
|
2025
Q2 | $708K | Sell |
38,000
-18,100
| -32% | -$358K | ﹤0.01% | 7813 |
|
|
2025
Q1 | $1.07M | Buy |
56,100
+4,100
| +8% | +$120K | ﹤0.01% | 6802 |
|
|
2024
Q4 | $1.87M | Buy |
52,000
+31,400
| +152% | +$1.06M | ﹤0.01% | 5765 |
|
|
2024
Q3 | $874K | Sell |
20,600
-39,400
| -66% | -$1.67M | ﹤0.01% | 7133 |
|
|
2024
Q2 | $2.42M | Buy |
60,000
+44,800
| +295% | +$1.87M | ﹤0.01% | 4964 |
|
|
2024
Q1 | $538K | Sell |
15,200
-4,600
| -23% | -$123K | ﹤0.01% | 8225 |
|
|
2023
Q4 | $586K | Sell |
19,800
-26,000
| -57% | -$539K | ﹤0.01% | 7746 |
|
|
2023
Q3 | $951K | Buy |
45,800
+6,900
| +18% | +$190K | ﹤0.01% | 6655 |
|
|
2023
Q2 | $955K | Sell |
38,900
-24,600
| -39% | -$791K | ﹤0.01% | 6555 |
|
|
2023
Q1 | $2.58M | Sell |
63,500
-17,200
| -21% | -$712K | ﹤0.01% | 4896 |
|
|
2022
Q4 | $3.63M | Sell |
80,700
-44,800
| -36% | -$2.03M | ﹤0.01% | 4428 |
|
|
2022
Q3 | $6M | Buy |
125,500
+33,900
| +37% | +$1.86M | ﹤0.01% | 3566 |
|
|
2022
Q2 | $5.42M | Buy |
91,600
+37,000
| +68% | +$3.04M | ﹤0.01% | 3648 |
|
|
2022
Q1 | $6.35M | Sell |
54,600
-121,300
| -69% | -$14.2M | ﹤0.01% | 3720 |
|
|
2021
Q4 | $26.5M | Buy |
175,900
+40,500
| +30% | +$5.47M | 0.01% | 1724 |
|
|
2021
Q3 | $16.2M | Buy |
135,400
+34,400
| +34% | +$3.79M | ﹤0.01% | 2306 |
|
|
2021
Q2 | $9.84M | Sell |
101,000
-70,700
| -41% | -$6.3M | ﹤0.01% | 3107 |
|
|
2021
Q1 | $15.2M | Sell |
171,700
-32,200
| -16% | -$2.99M | ﹤0.01% | 2351 |
|
|
2020
Q4 | $19.5M | Buy |
203,900
+67,700
| +50% | +$6.98M | 0.01% | 1832 |
|
|
2020
Q3 | $15.5M | Buy |
136,200
+700
| +0.5% | +$73.5K | ﹤0.01% | 1803 |
|
|
2020
Q2 | $13.4M | Buy |
135,500
+12,600
| +10% | +$1.01M | ﹤0.01% | 1892 |
|
|
2020
Q1 | $7.91M | Sell |
122,900
-132,100
| -52% | -$9.26M | ﹤0.01% | 2134 |
|
|
2019
Q4 | $15.2M | Buy |
255,000
+13,000
| +5% | +$802K | 0.01% | 1756 |
|
|
2019
Q3 | $14.3M | Buy |
242,000
+66,800
| +38% | +$4.26M | 0.01% | 1825 |
|
|
2019
Q2 | $11.3M | Buy |
175,200
+10,800
| +7% | +$697K | 0.01% | 2040 |
|
|
2019
Q1 | $10.4M | Buy |
164,400
+63,100
| +62% | +$3.31M | 0.01% | 2016 |
|
|
2018
Q4 | $3.85M | Sell |
101,300
-41,000
| -29% | -$1.45M | ﹤0.01% | 3170 |
|
|
2018
Q3 | $6.1M | Buy |
142,300
+99,500
| +232% | +$3.47M | ﹤0.01% | 2739 |
|
|
2018
Q2 | $942K | Buy |
+42,800
| New | +$526K | ﹤0.01% | 5326 |
|
|
2017
Q1 | – | Sell |
-1,560
| Closed | -$34K | – | 8047 |
|
|
2016
Q4 | $34K | Buy |
+1,560
| New | +$60K | ﹤0.01% | 6962 |
|
Other funds holding TNDM
SC
VPM
ACH
VCM
GKIM
DCM
Citadel Advisors's TNDM Position: Q1 2026 in Review
Citadel Advisors increased its Tandem Diabetes Care (TNDM) stake by 5% in Q1 2026, buying an estimated $2.26M and bringing the position to 2,192,667 shares worth $42M. The position accounts for 0.01% of the portfolio, ranked #1524.
Citadel Advisors first reported a position in TNDM in Q2 2015 and has held it in 35 quarters since. The position peaked at $122M in Q4 2021. 272 funds tracked by Wall St. Rank hold TNDM as of Q1 2026.
- Citadel Advisors held 2,192,667 shares of Tandem Diabetes Care worth $42M as of Q1 2026.
- Citadel Advisors bought 104,064 Tandem Diabetes Care shares in Q1 2026, an estimated $2.26M.
- Tandem Diabetes Care made up 0.01% of Citadel Advisors's portfolio in Q1 2026, its #1524 holding.
- Citadel Advisors first reported a position in Tandem Diabetes Care in Q2 2015 and has held it in 35 quarters since.
- Citadel Advisors's Tandem Diabetes Care position peaked at $122M in Q4 2021.
- 272 funds tracked by Wall St. Rank held Tandem Diabetes Care as of Q1 2026.
Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.